TARGET AUDIENCE
This activity is intended for clinical nurse specialists, nurse practitioners and registered nurses.
LEARNING OBJECTIVES
- Apply the oncology principles discussed to the care of patients with NSCLC.
- Explore new supportive and therapeutic strategies to enhance the care of patients with NSCLC.
ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by Research To Practice during the period of March 2011 through March 2012.
HOW TO USE THIS CNE ACTIVITY
This CNE activity contains a video component. To receive credit, the participant should watch the video content and complete the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/IOLLung11/CNE.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Beth Eaby-Sandy, MSN, CRNP, OCN
Nurse Practitioner
Outpatient Thoracic Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Advisory Committee: Novartis Pharmaceuticals Corporation; Speakers Bureau: Genentech BioOncology, Sanofi.
Rogerio C Lilenbaum, MD
Chairman, Cancer Institute
Cleveland Clinic Florida
Weston, Florida
Consulting Agreements: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Genentech BioOncology, YM BioSciences Inc.
Mark A Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
Data and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals; Paid Research: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc; Speakers Bureau: Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Sanofi.
Michelle M Turner, MS, CRNP
Thoracic Oncology Nurse Practitioner
University of Maryland Marlene and Stewart Greenebaum Cancer Center
Member of the American Academy of Nurse Practitioners
Baltimore, Maryland
Speakers Bureau: Genentech BioOncology.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals
Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This program is supported by an educational grant from Lilly USA LLC.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: March 2011
Expiration date: March 2012
